1 Longitudinal trajectories of muscle impairments in growing boys with

2 Duchenne muscular dystrophy

3	
4	
5	Ines Vandekerckhove ¹ – Marleen Van den Hauwe ^{1,2} – Tijl Dewit ^{1,3} – Geert Molenberghs ^{4,5} – Nathalie
6	Goemans ^{2,6} – Liesbeth De Waele ^{2,6} – Anja Van Campenhout ^{6,7} – Friedl De Groote ⁸ – Kaat Desloovere ^{1,3*}
7	
8	
9	
10	
11	¹ Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium
12	² Department of Child Neurology, University Hospital Leuven, Leuven, Belgium
13	³ Clinical Motion Analysis Laboratory, University Hospital Leuven, Pellenberg, Belgium
14 15	⁴ Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven, Belgium
16 17	⁵ Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Hasselt, Belgium
18	⁶ Department of Development and Regeneration, KU Leuven, Leuven, Belgium
19	⁷ Department of Orthopedics, University Hospital Leuven, Leuven, Belgium
20	⁸ Department of Movement Sciences, KU Leuven, Leuven, Belgium
21	
22	
23	
24	
25	* Corresponding author

26 ENDTEIL THE Propriet Action of the second state of the second s

27 Abstract

28 Background

Insights into the progression of muscle impairments in growing boys with Duchenne muscular dystrophy (DMD) remains incomplete due to the frequent oversight of normal maturation as confounding factor, thereby restricting the delineation of sole pathological processes.

32 Objective

To establish longitudinal trajectories for a comprehensive integrated set of muscle impairments, including muscle weakness, contractures and muscle size alterations, whilst correcting for normal maturation, in DMD.

36 Methods

37 Thirty-five boys with DMD (aged 4.3-17 years) were included. Fixed dynamometry, goniometry and 3D 38 freehand ultrasound were used to repeatedly asses lower limb muscle strength, passive range of 39 motion (ROM) and muscle size, resulting in 165, 182 and 67 assessments for the strength, ROM and 40 ultrasound dataset, respectively. To account for natural strength development, ROM reduction and 41 muscle growth in growing children, muscle impairments were converted to unit-less z-scores 42 calculated in reference to typically developing (TD) peers. This allows the interpretation of the muscle 43 impairments as deficits or alterations with respect to TD. Mixed-effect models estimated the 44 longitudinal change in muscle impairments.

45 **Results**

The pathological trajectories of most muscle impairments with age followed a similar non-linear, piecewise pattern, characterized by an initial phase of improvement or stability lasting until 6.6-9.5 years, and a subsequent decline after these ages. The muscle strength outcomes and several ROMs

showed already initial deficits at young ages. General muscle weakness and plantar flexion
contractures exhibited the steepest declines, resulting in large deficits at older ages. The muscle size
alterations with age were muscle-specific.

52 Conclusions

- 53 The established longitudinal trajectories of muscle impairments will serve as the basis to enhance
- 54 understanding of their relationship with the progressive gait pathology in DMD. Our study provides
- 55 outcome measures, which will be useful for future clinical trials that assess the efficacy of novel
- 56 therapeutic strategies.

58 Introduction

59 Duchenne muscular dystrophy (DMD) is an X-linked progressive muscular disorder, affecting one per 60 3,500-6,000 newborn boys [1–3]. It causes dystrophin deficiency that increases muscle cell membrane fragility and vulnerability to contraction-induced damage [4–6]. Progressive muscle degeneration then 61 62 emerges with loss of contractile tissue and replacement by fat and fibrotic tissue [2,7]. Boys with DMD exhibit progressive muscle impairments, including muscle size alterations, weakness and contractures 63 64 [1,2,8,9]. These muscle impairments contribute to alterations in posture and gait, reflected in a motor 65 function decline with loss of ambulation between the ages of 7.1 and 18.6 years (mean age: 12.7 years) [1,2,10]. The state-of-the-art standard of care has altered the natural disease course and has increased 66 67 life expectancy in DMD [2,11–14]. One of the treatment goals in DMD is prolonging ambulation [1,2]. 68 However, previous studies showed conflicting results on orthopedic and orthotic interventions that 69 aim at optimizing gait and motor performance [15–19]. Since many treatment options target muscle 70 impairments, an improved understanding of how underlying muscle impairments contribute to gait 71 pathology in DMD is essential to improve clinical decision making and to make progress in 72 rehabilitation, orthotic and orthopedic treatments. Furthermore, promising novel clinical trials could 73 potentially slow down disease progression and delay loss of ambulation, but their clinical development 74 has been hampered due to the lack of sensitive outcome measures and natural history data [20–23]. 75 To these ends, we first need to establish longitudinal trajectories of muscle impairments. This will 76 enrich natural history data and reveal sensitive outcome measures, and may eventually be used to 77 enhance our understanding of their relationship with progressive gait pathology.

78

Progressive muscle weakness is the primary clinical symptom in DMD. McDonald et al.[24] reported that muscle strength declined at an average rate of -0.25 manual muscle testing (MMT) units over 20 muscle groups of the neck, trunk, upper and lower limb, over a period of one year, in boys aged between 5 and 13 years. However, MMT is rather subjective and appears to have restricted reliability,

83 accuracy and sensitivity [25–27]. Objective dynamometry is, therefore, preferred for evaluating muscle 84 weakness [28]. Significant weakness, evaluated through dynamometry, has been observed already in young boys with DMD and the strength deficit relative to typically developing (TD) children increased 85 86 further with age [28–30]. This was primarily the result of the large age-related increase in muscle 87 strength in TD, while in DMD absolute muscle strength remained relatively constant between the ages 88 of 5 and 14 years [28,30]. After accounting for growth by normalizing muscle strength to body surface 89 area or body mass, a significant reduction in strength with age was detected in boys with DMD [28,29]. 90 Additionally, the use of more complex statistical models, such as non-linear piecewise models, showed 91 that absolute muscle strength increased or remained stable until 8.5 years and then declined with age 92 [31]. Moreover, mostly cross-sectional analyses have been performed, and therefore, caution is 93 needed with interpreting cross-sectional age-effect as longitudinal disease progression. A previous 94 longitudinal analysis indicated that absolute knee extension/flexion strength increased until the age of 95 7.5 years, while after the age of 7.5 years strength declined, with even a more pronounced decline 96 after 9 years of age [31]. Recently, Leon et al. [32] generated percentile curves of muscle strength for 97 boys with DMD aged 4 to 18 years based on an extended longitudinal dataset consisting of 230 98 assessments in 73 boys. Knee extension strength exhibited the most pronounced decline, followed by 99 hip flexion strength, and then knee flexion strength. A recent 8-year longitudinal study of Buckon et 100 al.[33] delineated the progressive muscle weakness in boys with DMD (aged 4 to 15 years at baseline), 101 comparing those treated with corticosteroids (n=70) and those who were treatment-naïve (n=14). They found that knee extension strength, followed by hip extension strength, declined fastest and, 102 103 that corticosteroid therapy slowed the rate of decline in knee extension strength by three times 104 compared to treatment-naïve boys.

105

Apart from progressive muscle weakness, also other impairments occur in boys with DMD. Due to fat
 and fibrotic tissue infiltration into the muscles, prolonged static positioning and muscle weakness, boys
 with DMD experience progressive loss of passive range of motion (ROM), resulting in the development

109 of contractures [8]. Whereas ankle plantar flexion contractures develop first, hip flexion, knee flexion 110 and hip abduction contractures are also frequently present in boys with DMD [8,24,34]. In general, 111 lower limb contractures are strongly related to wheelchair reliance [8,24,34,35]. Even though boys 112 with DMD are longer ambulant with the widespread use of corticosteroids [36], the pattern of slow 113 contracture evolution prior to loss of ambulation and rapid contracture evolution following loss of 114 ambulation has persisted [24,34,35]. Choi et al.[35] found that 52.6% in the ambulatory group had 115 ankle plantar flexion contractures and Willcocks et al. [34] showed that ROM was significantly lower in 116 DMD than in TD, 5 years prior to loss of ambulation at the ankle, 2 years prior to loss of ambulation at 117 the knee and 4 years prior to loss of ambulation at the hip. However, most studies focused on frequency and severity of contractures, while a quantification of the progression rate of decreasing 118 119 ROM based on large longitudinal datasets is scarce. The longitudinal picture of contracture 120 development and impact of treatment is important to be outlined, to relate these changes with the 121 progressive gait pathology. Based on an extended longitudinal study of 1761 assessments in 322 boys 122 with DMD, Kiefer et al.[37] found that ankle dorsiflexion ROM decreased with 1.43 degrees per year. 123 Furthermore, Leon et al.[32] generated percentile curves for ankle dorsiflexion ROM with knee flexed 124 and extended based on a longitudinal dataset of 258 assessments in 73 boys with DMD. The ankle 125 dorsiflexion ROM gradually declined with age. Negative ROM values (i.e., ROM deficit to reach the 126 neutral ankle angle of 90°) were observed from 8 years onwards with knee extended and from 9 years 127 onwards with knee flexed, highlighting a pathological shortening in ankle plantar flexors [32]. However, 128 previous studies did not account for the typical reduction in ROM observed in TD children aged 2 to 17 129 years [38-40].

130

The progressive loss of contractile tissue and proliferation of fat and fibrotic tissue result in varying muscle size alterations, such as profound atrophy in some muscles and (pseudo)hypertrophy in others [9]. (Pseudo)hypertrophy of the m. triceps surae is a well-known feature in DMD with reported similar contractile cross-sectional area (CSA) as in TD [9] but a total CSA up to 60% larger than in TD [28]. Yet,

135 results on the change in m. triceps surae size with age in DMD are conflicting [9,28]. The m. quadriceps 136 has been characterized by atrophy in DMD, with both smaller contractile and total CSA than in TD [9]. 137 However, Mathur et al. [28] found hypertrophy of the m. quadriceps under the age of 10 years and 138 atrophy from the age of 11 years. While the m. triceps surae and m. quadriceps represent two ends of 139 a spectrum, the m. hamstrings and m. tibialis anterior presented with less distinctive muscle size 140 alterations [9]. Magnetic resonance imaging (MRI) has been frequently used to quantify muscle size as 141 well as composition and has repeatedly been suggested as sensitive biomarker in DMD clinical trials 142 [41–45]. Ultrasound has some advantages over MRI, since it is child-friendly, relatively cheap, fast, 143 does not require sedation, and is clinically easily accessible because it can be collected using a portable device. Ultrasound studies showed that changes in muscle echo-intensity preceded motor regression 144 145 and increased over time, highlighting the added value of ultrasound as practical and child-friendly 146 estimate of muscle composition as an outcome measure for the longitudinal follow-up of disease 147 progression [46–48]. However, studies evaluating muscle size with ultrasound in DMD are scarce. Bulut 148 et al.[49] reported increased muscle thickness of the m. vastus lateralis and m. medial gastrocnemius 149 in children with DMD compared to TD children. However, Jansen et al.[47] and Pillen et al.[50] only 150 found a reduced muscle thickness of the m. guadriceps muscle at baseline without abnormalities in 151 thickness of the other muscles. Morse et al.[51] even showed a decrease of 36% in CSA of the m. medial 152 gastrocnemius in adults with DMD compared to TD adults. Additionally, a longitudinal analysis 153 indicated that muscle thickness normalized to body mass of the lower limb muscles did not progress 154 with age [47], while another study demonstrated larger absolute muscle thickness of the m. medial gastrocnemius in more severely affected boys than in less severely affected boys [49]. This highlights 155 156 that the longitudinal evolution of muscle size alterations measured by ultrasound in growing boys with 157 DMD is still unclear.

158

159 It can be concluded that the insights into the progression of muscle impairments in boys with DMD160 during growth remain incomplete. This inadequacy arises from the fact that not all lower-limb muscle

161 groups have undergone comprehensive assessment, and conflicting results among studies have been 162 reported. Additionally, the confounding factor of normal maturation has frequently been overlooked, 163 or various normalization techniques have been inconsistently applied. Therefore, it has been difficult 164 to distinguish pathological changes from typical strength development, ROM reduction, and muscle 165 growth observed in TD, hampering the interpretation of pure pathological processes during growth in 166 DMD. We recently developed anthropometric-related TD percentile curves for muscle strength and 167 size [52]. These curves enable us to convert individual muscle strength and size outcomes into unit-168 less z-scores, which indicate deficits relative to TD peers. Since this way typical strength development 169 and normal muscle growth are accounted for, the use of z-scores facilitates the interpretation of 170 pathological alterations during growth. Similarly, the TD reference values of Mudge et al.[38] and 171 Sankar et al.[39] for three age groups can be used to calculate unit-less z-scores for ROM, allowing to 172 correct for the typical reduction in ROM observed in TD. Therefore, the aim of this study was to 173 establish longitudinal trajectories for a comprehensive integrated set of muscle impairments, including 174 muscle weakness, contractures, and muscle size alterations, whilst correcting for normal maturation, 175 in growing boys with DMD through a longitudinal follow-up design.

176 Materials and methods

177 Study design and participants

This longitudinal observational cohort study was designed with a protocol of repeated assessments with a variable number of assessments between participants and variable time intervals between assessments.

181 Children with DMD were recruited via the multidisciplinary clinic of the Neuromuscular Reference 182 Centre (NMRC) in the University Hospital Leuven campus Gasthuisberg between 22 June 2018 and 31 183 December 2022. Boys aged between 3 and 16 years at baseline, ambulatory for at least 100 meters, 184 and with a confirmed genetic diagnosis of DMD, were included. Cognitive and behavioral disorders preventing accurate measurements, a clinical picture of Becker muscular dystrophy, and history of muscle lengthening surgery were exclusion criteria. Use of corticosteroids and participation in clinical trials were permitted. At the University Hospital Leuven, a proactive/preventive policy was implemented to address contractures. Hereto, night-time ankle foot orthoses (AFOs) were initiated before any contractures occurred, often in conjunction with the start of corticosteroids. Occasionally, serial casting was also employed to manage early losses in ankle dorsiflexion ROM.

- 191 Retrospective data from the included children collected before 14 June 2018 (between 20 May 2015
- and 14 June 2018) was accessed through the database of University Hospital Leuven between 22 June
- 193 2018 and 31 December 2022.

The local ethics committee (Ethical Committee UZ Leuven/KU Leuven; S61324) approved this study under the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. The parents or caregivers of the participants signed a written informed consent and participants aged 12 years or older signed a written informed assent.

198

199 Data collection and analysis

200 Muscle strength and size were collected unilaterally. The weakest side based on MMT was selected as 201 the assessed side. Contractures were assessed bilaterally, but only the values of the weakest side were 202 included in further analyses, to ensure consistency with the other measurements. If no weakest side 203 could be identified, the assessed side was randomly chosen.

204 Anthropometry

Body mass, height and lower limb segment lengths of the boys with DMD were measured at eachfollow-up session.

207 Muscle weakness

A reliable and valid instrumented strength assessment was used to evaluate muscle weakness of the
 hip extensors, hip flexors, hip abductors, knee extensors, knee flexors, plantar flexors, and dorsiflexors

210 [53,54]. The participants performed maximal voluntary isometric contractions (MVIC) using a fixed 211 dynamometer (MicroFet, Hogan Health Industries, West Jordan, UT United States) in a standardized 212 test position. Custom-written matlab (The Mathworks Inc., Natick, M.A., R2021b) scripts were used to 213 extract the maximal force (in Newton) per MVIC and to calculate the mean maximal joint torque (in 214 Newton meter) per muscle group by multiplying the mean maximal force over one to three 215 representative MVIC trials with the lever arm, which was determined as 75% of the segment length. 216 To account for typical strength development, anthropometric-related TD percentile curves for muscle 217 strength (n=153) were used to convert mean maximal joint torques into unit-less z-scores [52]. Hence, 218 these z-scores reflect muscle strength deficits with respect to TD peers.

219 Contractures

220 During a standardized clinical examination, goniometry was used to measure the passive ROM of hip 221 extension (modified Thomas test [38]), hip adduction (with extended hip and knee of the assessed leg 222 and hip and knee flexed in 90° of the contralateral leg), knee extension [38], hamstrings (true popliteal 223 angle [38]), and ankle dorsiflexion (with knee extended and knee flexed in 90° [38]). Previous studies 224 reported acceptable intra-rater and inter-rater reliability of these measures [38]. Passive ROM was 225 measured in degrees. Since TD percentile curves for ROM are currently lacking, the age-related 226 normative reference values of Mudge et al.[38] were used to convert ROM measures into unit-less z-227 scores, accounting for the typical reduction in passive ROM during growth. Thereby, the normative 228 mean of the corresponding age group (4-7 years, 8-11 years and 12-16 years) was subtracted from the 229 individual ROM and then this difference was divided by the standard deviation of the total normative 230 group. We decided to use the standard deviation of the total normative group, since the large 231 difference in standard deviations between normative age groups would result in unrealistic changes in 232 z-scores over time. A similar approach was used to calculate z-scores for hip adduction ROM, but based 233 on the reference values for three age groups provided by Sankar et al.[39], since these were lacking in 234 the study of Mudge et al. [38]. By calculating the z-scores based on data for three age groups,

235 continuous changes with age were not fully controlled for, influencing the validity of z-scores.

Therefore, both absolute ROM (in degrees) and unit-less ROM (in z-scores) were reported.

237 Muscle size alterations

238 The reliable 3D freehand ultrasonography (3DfUS) was used to assess muscle size alterations of the m. 239 rectus femoris, m. medial gastrocnemius and m. tibialis anterior [55,56]. The orientation and position 240 of 2D ultrasound images were quantified using a motion tracking system (Optitrack V120:Trio, 241 NaturalPoint Inc., Corvallis, Oregon, USA) that tracked four reflective markers on the linear probe of a 242 Telemed-Echoblaster B-mode ultrasound device (Telemed-Echoblaster 128 Ext-1Z, with a 5.9-cm 10-243 MHz linear US transducer, Telemed Ltd., Vilnius, Lithuania). To limit muscle deformation, a custom-244 made gel pad (i.e., the portico), was attached on the ultrasound probe [57]. Data was collected and 245 processed using STRADWIN software (version 6.0; Mechanical Engineering, Cambridge University, 246 Cambridge, UK). The Euclidean distances between relevant anatomical landmarks were calculated to 247 estimate muscle lengths (in mm). Mid-belly anatomical CSA (in mm²) was defined by one manually 248 drawn transverse plane segmentation alongside the inner muscle border at 50% of the muscle length. 249 We applied the same ultrasound settings and parameter definition as reported in previous studies 250 [56,58]. In some children, high muscle degeneration strongly reduced the visibility of the muscle 251 border. In those children, a single 2D image was collected at the mid-belly. Real-time feedback from 252 the ultrasound images and palpation of the leg were used to identify landmarks. Subsequently, a tape 253 measure was used to determine the midpoint between landmarks (i.e., mid-belly). To account for 254 typical muscle growth, anthropometric-related TD percentile curves for muscle CSA (n=143) were used 255 to convert CSA into unit-less z-scores [52]. Hence, these z-scores reflect muscle size alterations with 256 respect to TD peers.

257

258 Statistical analysis

259 To model the longitudinal change in muscle impairments, (non-)linear mixed-effect models were used.

260 Mixed models were fitted per outcome, i.e., strength of the 7 muscle groups (expressed as z-scores), 261 6 passive ROMs (absolute (in degrees) as well as unit-less (in z-scores)) and 3 muscle CSAs (expressed 262 in z-scores). The mixed models consisted of a mean structure (i.e., fixed effects) to delineate the 263 average trajectory and a covariance structure, induced by random effects, to describe the inter-subject 264 variability. Age (expressed in years) at each repeated assessment represented the time-effect and was 265 selected as the fixed effect. Random effects were included to model the variability in starting point 266 (i.e., random intercept) and the variability in trajectory (i.e., random slope) among the subjects. We 267 applied the previously documented workflow to construct the mixed-effect models [59–61]. Since the 268 explorations suggested linear trends interrupted by breaking points, non-linear piecewise models were 269 allowed. Thereby, estimated values from the explorations were used as starting values and the 270 presence of multiple breakpoints was investigated. A breakpoint was defined if the F-test detected a 271 significant change between adjacent slopes, whilst ensuring a minimum of 10 datapoints per 272 regression line. Moreover, a breakpoint was not interpreted as a strict age where a change occurs, but 273 rather as the approximate age around which a change in rate occurs. Non-nested linear and non-linear 274 piecewise models were compared using the Akaike information criterion (AIC). Since, overall, the 275 piecewise models demonstrated the smallest AIC, these models were selected. Yet, the difference with 276 the linear models was small and we therefore documented the linear models in the supplementary 277 materials (S1-S3 Figs and S1-S3 Tables). The piecewise model with observation *j* in subject *i* to estimate 278 the outcome_{ii} was defined as follows:

279

$$\begin{array}{ll} 280 & Outcome_{ij} = (\alpha_0 + a_{i0}) + (\beta_1 + b_{i1}) * age_{ij} + \varepsilon_{ij} & \text{if } age_{ij} < \gamma_1 \\ \\ 281 & Outcome_{ij} = (\alpha_0 + a_{i0}) + \gamma_1 * ((\beta_1 + b_{i1}) - (\beta_2 + b_{i2})) + (\beta_2 + b_{i2}) * age_{ij} + \varepsilon_{ij} & \text{if } \gamma_1 \leq age_{ij} < \gamma_2 \\ \\ 282 & Outcome_{ij} = (\alpha_0 + a_{i0}) + \gamma_1 * ((\beta_1 + b_{i1}) - (\beta_2 + b_{i2})) + \gamma_2 * ((\beta_2 + b_{i2}) - (\beta_3 + b_{i3})) \\ & + (\beta_3 + b_{i3}) * age_{ij} + \varepsilon_{ij} & \text{if } \gamma_2 \leq age_{ij} \end{array}$$

283

with α_0 = intercept; a_{i0} = random intercept; β_1 = regression slope if $age_{ij} < \gamma_1$; b_{i1} = random slope of β_1 ; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \le age_{ij} < \gamma_2$; b_{i2} = random slope of β_2 ; γ_2 = second

286 breakpoint; β_3 = regression slope if $\gamma_2 \le age_{ij}$; b_{i3} = random slope of β_3 ; γ_1 = first breakpoint; ϵ_{ij} = 287 measurement error.

F-tests were performed to investigate if the intercepts, regression slopes and breakpoints differed from zero. The significance threshold was set to $\alpha = 0.05$. So-called empirical Bayes estimates were calculated after model formulation and used to detect outliers, i.e., subjects with an exceptional starting point and/or evolution with age. Data of outliers were checked. SAS[®] (version 9.4, Statistical Analysis Software, SAS Institute Inc., Cary, NC, USA) was used to conduct all analyses and visualizations.

293 **Results**

Thirty-five boys with DMD, aged between 4.3 and 17 years old, were repeatedly measured between 2015 and 2022 at multiple time points (1 to 11) with a variable time interval of 5-35 months, covering a follow-up period of 6 months to 6.6 years. In total, the collected dataset consisted of 185 observations (Table 1 and S4 Fig). After data collection and processing, quality check and outliers removal, the strength dataset consisted of 165 observations in 33 boys, the ROM dataset of 182 observations in 34 boys and the ultrasound dataset of 67 observations in 34 boys.

301 Table 1. Group demographics

Baseline characteristics						
Subjects (n)	35					
Median age (Q1-Q3)	7.6 years (4.9-9.9)					
Median body mass (Q1-Q3)	22.4 kg (18.3-33.8)					
Median height (Q1-Q3)	1.16 m (1.01-1.29)					
Median BMI (Q1-Q3)	17.1 kg/m ² (15.5-19.1)					
Corticosteroids						
Daily Deflazacort (% subjects)	77.10%					
Vamorolone (% subjects)	/					
No steroids (% subjects)	22.90%					
Participation in clinical trial with disease	200/					
modifying medication (% subjects)	2070					
Adherence night-time ankle foot orthoses	82 000/					
(% subjects)	82.90%					
Serial casting (% subjects)	2.90%					
Characteristics over all obs	ervations					
Subjects (n)	35					
Observations (n)	185					
Median age (Q1-Q3)	10.1 years (7.6-12.5)					
Median body mass (Q1-Q3)	30.4 kg (22.4-40.4)					
Median height (Q1-Q3)	1.23 m (1.14-1.31)					
Median BMI (Q1-Q3)	18.9 kg/m ² (16.8-24.1)					
Corticosteroids						
Daily Deflazacort (% observations)	92.40%					
Vamorolone (% observations)	2.20%					
No steroids (% observations)	5.40%					
Participation in clinical trial with disease	26 800/					
modifying medication (% observations)	50.8070					
Adherence night-time ankle foot orthoses	78 00%					
(% observations)	/0.70/0					
Serial casting (% observations)	6.50%					
Loss of ambulation (% subjects)	31.40%					

302

303 Muscle weakness

304	The longitudinal trajectories of muscle strength deficits were characterized by piecewise trends (Fig 1
305	and Table 2). Hip extension strength tended to increase with a rate of 0.93 z-score/year from a z-score
306	of -3.6 z-score at 4.9 years to a z-score of -2 at age 6.6 years and then decreased with a rate of -0.29 z-
307	score/year until a z-score of -4.9 at 16.4 years. Hip flexion strength increased with 1.03 z-score/year
308	from -2.5 z-score at age 4.9 years to -0.7 z-score at age 6.7 years and then decreased with -0.29 z-
309	score/year until -3.5 z-score at age 16.4 years. Hip abduction strength was -2.2 z-score at age 4.9 years
310	and remained constant until age 8.5 years. It then decreased with -0.44 z-score/year from -1.5 z-score
311	at age 8.5 years to -5 z-score at age 16.4 years. Knee extension strength was -0.7 z-score at age 4.6
312	years and remained constant until age 7.3 years. It then decreased with -0.48 z-score/year from -0.4
313	z-score at age 7.3 years to -4.8 z-score at age 16.4 years. Knee flexion strength was -1.5 z-score at age

314	4.6 years and remained constant until 8.6 years. It then decreased with a rate of -0.25 z-score/year
315	from -1.3 z-score at age 8.6 years to -3.2 z-score at age 16.4 years. Ankle plantar flexion tended to
316	increase with a rate of 0.25 z-score/year from -2.1 z-score at age 4.6 years to -1 z-score at age 9.1 years
317	and then decreased with -0.39 z-score/year until -3.8 z-score at age 16.4 years. Ankle dorsiflexion
318	strength was -2.3 z-score at age 4.6 years and remained constant until age 8.5 years. It then decreased
319	with -0.33 z-score/year from -1.8 z-score at age 8.5 years to -4.5 z-score at age 16.4 years.
320	
321	Fig 1. Predicted longitudinal trajectories for muscle strength deficits of hip muscles (a), knee muscles
322	(b) and ankle muscles (c) with age for boys with DMD. The average predicted trajectory (black tick
323	line), the individual predicted profiles (colored thinner lines), and the actual observed outcomes

- 324 (colored dots) are displayed. Each color represents one patient with DMD. The estimates for the fixed
- 325 effects are given in Table 1. DMD, Duchenne muscular dystrophy

326 Table 2. Fixed effects of piecewise models for the longitudinal trajectories of the muscle strength deficits with age for boys with DMD

			Intercept	Regression coefficients (β) and breakpoints (γ)			
			α ₀ (CI)	β ₁ (CI)	γ1 (CI)	β ₂ (CI)	
Outcomes	n subj	n obs	p-value	p-value	p-value	p-value	
Hip extension strength	22	144	-8.16 (-13.91 -2.40)	0.93 (-0.05 1.90)	6.61 (5.85 7.37)	-0.29 (-0.48 -0.09)	
(z-score)	33	144	0.0070	0.0613	<0.0001	0.0061	
Hip flexion strength	22	144	-7.51 (-12.16 -2.87)	1.03 (0.23 1.83)	6.66 (5.90 7.41)	-0.29 (-0.41 -0.16)	
(z-score)	33	144	0.0024	0.0131	<0.0001	<0.0001	
Hip abduction strength	22	142	-3.12 (-5.01 -1.23)	0.19 (-0.08 0.47)	8.52 (7.26 9.78)	-0.44 (-0.57 -0.32)	
(z-score)	33	143	0.0020	0.1654	<0.0001	<0.0001	
Knee extension strength	22	165	-1.18 (-2.19 -0.17)	0.10 (-0.05 0.26)	7.31 (6.43 8.18)	-0.48 (-0.60 -0.36)	
(z-score)	33		0.0234	0.1813	<0.0001	<0.0001	
Knee flexion strength	22	165	-1.78 (-4.16 0.61)	0.06 (-0.23 0.34)	8.63 (8.63 8.63)	-0.25 (-0.33 -0.17)	
(z-score)	33	105	0.1389	0.6953	<0.0001	<0.0001	
Plantar flexion strength	22	165	-3.22 (-5.15 -1.29)	0.25 (-0.02 0.51)	9.05 (7.80 10.29)	-0.39 (-0.58 -0.20)	
(z-score)	33	105	0.0019	0.0674	<0.0001	0.0003	
Dorsiflexion strength	22	165	-2.86 (-4.90 -0.83)	0.12 (-0.16 0.40)	8.45 (7.58 9.32)	-0.33 (-0.44 -0.23)	
(z-score)	33	105	0.0073	0.3817	<0.0001	<0.0001	

327 p-values in bold indicate significance level at p < 0.05.

328 The following symbols represent: α_0 = intercept; β_1 = regression slope if age < γ_1 ; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \le age$.

329 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj, subjects

331 Contractures

332 The longitudinal trajectories of the ROMs revealed a clear degeneration solely for ankle dorsiflexion (Fig 2 and Table 3). The absolute ankle dorsiflexion ROM with knee extended was 8.3° at age 4.3 years 333 334 and remained constant until 8.1 years. It then decreased with -2.7°/year from 9.7° at age 8.1 years to 335 -8.9° at age 15.1 years, and lastly decreased with -1°/year until -10.7° at age 17 years. The unit-less 336 ankle dorsiflexion ROM with knee extended was -2.8 z-score at age 4.3 years and remained constant 337 until 8.6 years. It then decreased with -0.34 z-score/year from -2.6 z-score at age 8.6 years to -5.5 z-338 score at age 17 years. The absolute ankle dorsiflexion ROM with knee flexed was 15.7° at age 4.3 years 339 and remained constant until age 8.1 years. It then decreased with -2.2°/year from 15° at age 8.1 years 340 to -4.7° at age 17 years. The unit-less ankle dorsiflexion ROM with knee flexed was -2 z-score at age 341 4.3 years and remained constant until 8.2 years. It then decreased with -0.24 z-score/year from -2 z-342 score at age 8.2 years to -4.1 z-score at age 17 years. For hip extension and adduction ROM, no reliable 343 and valid mixed models could be fitted. The data exploration (S5 Fig) suggested, however, a subtle 344 downward trend for the absolute hip extension and adduction ROMs. At age 4.3 years, absolute and 345 unit-less knee extension ROMs were 2.5° and -0.5 z-score, respectively. For these outcomes, no 346 significant longitudinal change was found. Absolute hamstrings ROM was -39° at age 4.3 years, but did not progress with age. Unit-less hamstrings ROM increased with 0.10 z-score/year from -1.9 z-score at 347 348 age 4.3 years to -0.6 z-score at age 17 years.

349

Fig 2. Predicted longitudinal trajectories for absolute (left column) and unit-less (right column) knee extension ROM (a), Hamstrings ROM (b), ankle dorsiflexion with knee extended (c) and ankle dorsiflexion with knee flexed (d) with age for boys with DMD. The average predicted trajectory (black tick line), the individual predicted profiles (colored thinner lines), and the actual observed outcomes (colored dots) are displayed. Each color represents one patient with DMD. The estimates for the fixed effects are given in Table 2. DMD, Duchenne muscular dystrophy

356 Table 3. Fixed effects of piecewise models for the longitudinal trajectories of the absolute and unit-less ROMs with age for boys with DMD

			Intercept	Regression coefficients (β) and breakpoints (γ)					
			α ₀ (CI)	β ₁ (CI)	γ ₁ (CI)	β ₂ (CI)	γ ₂ (CI)	β ₃ (CI)	
Outcomes	n subj	n obs	p-value	p-value	p-value	p-value	p-value	p-value	
Knee extension ROM	24	190	-3.62 (-12.70 5.47)	1.42 (-0.32 3.16)	7.09 (4.83 9.35)	-0.42 (-0.97 0.14)			
(°)	54	160	0.4234	0.1063	<0.0001	0.1374			
Knee extension ROM	24	190	-1.72 (-3.55 0.10)	0.28 (-0.06 0.63)	7.09 (4.36 9.82)	0.01 (-0.09 0.12)			
(z-score)	54	180	0.0638	0.1041	<0.0001	0.8201			
Hamstrings ROM	24	100	-40.92 (-50.11 -31.72)	0.45 (-0.37 1.26)					
(°)	54	160	<0.0001	0.2797					
Hamstrings ROM	24	180	-2.32 (-3.21 -1.43)	0.10 (0.02 0.19)					
(z-score)	54		<0.0001	0.0169					
Dorsiflexion ROM	lexion ROM xtended (°) 34 18	34 182	6.64 (-1.31 14.58)	0.38 (-0.80 1.56)	8.12 (6.89 9.35)	-2.66 (-3.40 -1.92)	15.14 (13.54 16.75)	-0.95 (-1.87 -0.03)	
knee extended (°)			0.0987	0.5148	<0.0001	<0.0001	<0.0001	0.0442	
Dorsiflexion ROM	24	100	-2.99 (-4.34 -1.63)	0.04 (-0.14 0.22)	8.58 (8.58 8.58)	-0.34 (-0.52 -0.17)			
knee extended (z-score)	54	162	<0.0001	0.6556	<0.0001	0.0004			
Dorsiflexion ROM	24 1	24	100	16.50 (6.32 26.68)	-0.18 (-1.61 1.25)	8.12 (6.39 9.85)	-2.23 (-2.85 -1.60)		
knee flexed (°)	54	102	0.0023	0.7965	<0.0001	<0.0001			
Dorsiflexion ROM	ROM 34	102	-2.09 (-3.59 -0.58)	0.01 (-0.21 0.22)	8.19 (5.92 10.45)	-0.24 (-0.33 -0.14)			
knee flexed (z-score)		182	0.0082	0.9468	<0.0001	<0.0001			

p-values in bold indicate significance level at p < 0.05.

358 The following symbols represent: α_0 = intercept; β_1 = regression slope if age < γ_1 ; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \le age < \gamma_2$; γ_2 = second

359 breakpoint; β_3 = regression slope if $\gamma_2 \le$ age.

360 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; ROM, range of motion; subj, subjects

362 Muscle size alterations

363	The longitudinal trajectories of muscle size deficits were characterized by piecewise trends (Fig 3 and
364	Table 4). The m. rectus femoris CSA was 0.6 z-score at age 4.3 years and remained constant until age
365	8.8 years. It then decreased with -0.37 z-score/year from 1 z-score at age 8.8 years to -1.7 z-score at
366	age 16.2 years. The m. medialis gastrocnemius CSA was 3 z-score at age 4.3 years and remained
367	constant until age 9.5 years. It then decreased with -0.55 z-score/year from 4 z-score at age 9.5 years
368	to -0.1 z-score at age 17 years. The m. tibialis anterior CSA increased with 0.46 z-score/year from -0.1
369	z-score at age 4.3 years to 2 z-score at age 8.8 years, then decreased with -0.45 z-score/year until 0.3
370	z-score at age 12.5 years, and lastly remained relatively constant until 0.3 z-score at age 17 years.
371	
372	Fig 3. Predicted longitudinal trajectories for muscle size deficits with age for boys with DMD. The
373	average predicted trajectory (black tick line), the individual predicted profiles (colored thinner lines),
374	and the actual observed outcomes (colored dots) are displayed. Each color represents one patient with

375 DMD. The estimates for the fixed effects are given in Table 3. DMD, Duchenne muscular dystrophy

376 Table 4. Fixed effects of piecewise models for the longitudinal trajectories of the muscle size alterations with age for boys with DMD

			Intercept	Regression coefficients (β) and breakpoints (γ)				
			α ₀ (CI)	β ₁ (CI)	γ1 (CI)	β ₂ (CI)	γ ₂ (CI)	β ₃ (CI)
Outcomes	n subj	n obs	p-value	p-value	p-value	p-value	p-value	p-value
Rectus femoris	24	16	0.08 (-1.75 1.91)	0.11 (-0.16 0.37)	8.77 (6.58 10.97)	-0.37 (-0.62 -0.12)		
CSA (z-score)	24	40	0.9259	0.3994	<0.0001	0.0057		
Medial gastrocnemius	24	(7	2.16 (-1.87 6.19)	0.20 (-0.32 0.72)	9.46 (7.71 11.21)	-0.55 (-0.89 -0.21)		
CSA (z-score) 34		07	0.2840	0.4410	<0.0001	0.0024		
Tibialis anterior	20	()	-2.08 (-4.64 0.48)	0.46 (0.11 0.81)	8.82 (7.77 9.87)	-0.45 (-0.68 -0.22)	12.47 (12.47 12.47)	-0.01 (-0.25 0.22)
CSA (z-score)	CSA (z-score) 29		0.1072	0.0116	<0.0001	0.0004	<0.0001	0.9072

p-values in bold indicate significance level at p < 0.05.

378 The following symbols represent: α_0 = intercept; β_1 = regression slope if age < γ_1 ; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \le age < \gamma_2$; γ_2 = second

379 breakpoint; β_3 = regression slope if $\gamma_2 \leq$ age.

380 CI, 95% confidence interval; CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj, subjects

382 Discussion

383 This prospective longitudinal study established comprehensive trajectories of a combined set of 384 muscle impairments, consisting of muscle strength, contractures, and muscle size alterations, in the 385 same cohort of growing boys with DMD. We adjusted for typical strength development, ROM reduction 386 and muscle growth observed in TD by calculating unit-less z-scores in reference to TD peers. Therefore, 387 the established trajectories solely reflect pathological changes. This is the first study to describe 388 longitudinal trajectories for muscle impairments expressed as deficits or alterations in reference to TD. 389 The use of these unit-less z-scores allows for the comparison of pathological involvement between 390 muscle groups and different muscle impairments.

391

392 Muscle weakness in growing boys with DMD follows a non-linear longitudinal trajectory, illustrating 393 that its progression is more complex than a continuous increase. Initially, muscle strength improved 394 (for hip flexion) or remained stable (for all other muscle groups) and then declined after 6.6-9.5 years. 395 Lerario et al. also described muscle weakness at the knee as piecewise trends with initial improvements 396 before 7.5 years of age and declines after. The initial improvement or stable period is consistent with 397 the commonly held concept of the "honeymoon" period in DMD [62,63]. However, our results 398 indicated that boys with DMD are already weaker than TD children at young ages, which aligns with 399 previous literature [28-30]. Between muscle groups, the largest initial deficit was found for hip 400 extension strength, followed by hip flexion, dorsiflexion, hip abduction, plantar flexion, knee flexion, and lastly knee extension strength. This only partially conforms with the known pattern of proximal to 401 402 distal muscle weakness in DMD, since, unexpectedly, the ankle muscles were initially weaker than the 403 knee muscles. After the initial improvement or stable period, the strength deficit progression rate 404 changed to a decline at a certain age (i.e. breakpoint). Among muscle groups, this age did increase 405 according to the proximal to distal pattern of muscle weakness (with exception of hip abduction and 406 knee flexion). Indeed, hip extension and flexion strength began to decline at an earlier age than knee 407 extension strength, which was followed by ankle dorsiflexion and plantar flexion strength. Yet, the 408 decline rate was not compatible with this pattern. Specifically, knee extension strength showed the 409 steepest decline, followed by hip abduction, plantar flexion, dorsiflexion, hip extension and flexion, 410 and knee flexion strength. The variations in decline rate among muscle groups can be partially 411 attributed to the timing of the breakpoint and the existing initial weakness. Previous literature 412 reported a similar sequence of decline rate among muscle groups [32,33]. However, the longitudinal 413 trajectories are not entirely equivalent, but due to methodological discrepancies among the studies, 414 comparing the results proves challenging. Our results showed a flattening of the deterioration for hip 415 extension, hip flexion and knee extension strength through the linear models (S1 Fig and S1 Table). Such a ceiling effect has also been reported by previous literature, as muscles can only degenerate 416 417 until a certain point [24,47].

418

419 The trajectories of the ROMs revealed a clear decline solely for ankle dorsiflexion. In DMD, ankle 420 plantar flexion contractures are the first contractures to develop, and, hence, occur more frequently 421 and severely than hip and knee contractures in the ambulatory period [24,35]. Our results indicated 422 already important plantar flexion contractures at young ages, which further progressively increased 423 after the age of 8 years. Larger deficits were observed for dorsiflexion ROM with knee extended than 424 with knee flexed, suggesting that the gastrocnemius is more affected than the soleus in the boys with 425 DMD. Previous literature found that the absolute dorsiflexion ROM declined linearly from early ages 426 onwards [32,37], which is in contrast with the non-linear piecewise trajectories in the current results. 427 Although the observed decline rates in absolute dorsiflexion ROM were steeper than the previously 428 reported longitudinal results of Kiefer et al. [37], the boys with DMD in the current study lost the ability 429 to achieve neutral ankle angles at approximately 12 years of age with knee extended and at 430 approximately 14 years of age with knee flexed, which was at an older age than reported by Leon et 431 al.[32]. The proactive/preventive policy of addressing contractures with the early use of night-time 432 AFOs and occasional serial casting may have played an important role in retaining dorsiflexion ROM 433 during the initial stable phase and in delaying the inability to achieve neutral ankle angles. In contrast 434 to the distal plantar flexion contractures, proximal lower-extremity contractures develop slowly in the 435 ambulatory period but tend to progress rapidly after transitioning to the wheelchair [8,24,35]. The 436 data exploration of absolute hip extension ROM and, absolute and unit-less hip adduction ROMs 437 suggested a subtle downward trend (S5 Fig). Hip extension ROM already showed deficits in young 438 children, indicating early hip flexion contractures, but subsequently declined at a similar rate to that 439 observed in TD. Hip adduction ROM declined more rapidly than in TD children, yet it did not exhibit 440 large deficits initially, implying that hip abduction contractures are absent early on but could develop 441 after loss of ambulation. Although knee extension ROM did not progress with age and no deficit with 442 respect to TD was found on average, there was significant inter-subject variability, and three patients 443 presented with evident knee flexion contractures. Deficits in the hamstrings ROM were shown in young 444 children, reflecting early hamstrings contractures, but subsequently, the ROM slightly tended to catch 445 up that in TD children.

446

447 The trajectories of the muscle size alterations were muscle-specific, which aligns with previous 448 literature [9]. Our results indicated that the m. rectus femoris CSA was slightly increased with respect 449 to TD at young ages, but showed a decrease from the age of 8.8 years onwards, resulting in atrophy at 450 older ages. This aligns with the cross-sectional findings of Mathur et al. [28], who observed hypertrophy 451 of the m. quadriceps under the age of 10 years and atrophy from the age of 11 years. In contrast, our 452 results indicated obvious hypertrophy in the m. medial gastrocnemius, however with a decrease from 453 9.5 years of age. (Pseudo)hypertrophy is a well-known symptom of DMD and has been repeatedly 454 reported by previous studies [9,28,49]. Morse et al. [51] is, to the best of our knowledge, the only study 455 that reported atrophy of m. medial gastrocnemius, though in adults with DMD. Hence, our observed trajectory of the m. medial gastrocnemius CSA, i.e. decreasing hypertrophy, may result in atrophy at 456 457 adult ages. Although the m. rectus femoris and m. medial gastrocnemius CSAs displayed similar 458 longitudinal trajectories, both muscles were characterized by different pathological processes (i.e., m.

rectus femoris atrophy vs m. medial gastrocnemius hypertrophy), a finding also reported by the crosssectional study of Wokke et al. [9]. In line with the observations of Wokke et al. [9], the trajectory of
m. tibialis anterior CSA appeared less clearly defined with a high inter-subject variability.

462

463 This study provided novel insights by combining a set of different muscle impairments from multiple 464 muscle groups as well as by expressing them as deficits or alterations in reference to TD, thereby solely 465 revealing the pathological trajectories. Overall, the pathological trajectories of most muscle 466 impairments with age followed a similar non-linear, piecewise pattern, characterized by an initial 467 phase of improvement or stability lasting until 6.6-9.5 years, and a subsequent decline after these ages. 468 This indicates that despite the progressive nature of DMD, the deterioration of muscle impairments is 469 more complex than a steady decline. There is a period in which there is no deterioration (i.e., 470 honeymoon). Both the start of corticosteroids and the preventive use of night-time AFOs may 471 potentially play a significant role in this period of stability. However, all muscle strength outcomes 472 (except knee extension) and several ROMs, i.e., hip extension, m. hamstrings and ankle dorsiflexion 473 ROMs, showed already initial deficits in reference to TD early on at young ages. These proximal 474 contractures were already present in young boys with DMD, but did not further decline with age during 475 the ambulatory period. Conversely, general muscle weakness and plantar flexion contractures were 476 the most important muscle impairments that exhibited the steepest deteriorations after the initial 477 period of stability, resulting in large deficits at older ages. Moreover, the longitudinal trajectories of 478 deficits in muscle impairments appeared to be coupled. As such, it is interesting to note the decline in 479 muscle strength, ROM and CSA around the ankle, which all started around 8-9 years of age.

480

Although this study improved the insights into the longitudinal trajectories of muscle impairments in DMD based on a unique mixed longitudinal dataset, there were some limitations. The children with DMD enrolled in the study at different ages and the baseline age range was wide. Additionally, a limited number of repeated assessments was collected in some of the children with DMD. Moreover, the inter-

485 subject heterogeneity was high due to the differences in medical and clinical background such as 486 clinical trial participation, adherence to night-time AFOs, periods of serial casting, functional level, etc. (S4 Fig). More data is needed to delineate the influence of these background differences on the 487 488 longitudinal trajectories. For the strength measurements, we were dependent on the cooperation and 489 motivation of the children. Caution is needed with the interpretation of the unit-less ROMs 490 trajectories, as they were calculated based on age categories, which could result in abrupt changes in 491 the unit-less ROMs with age. This highlights the need for TD percentile curves for ROMs to aid in 492 distinguishing pathological reductions in ROM from the typical reduction in ROM during growth. Lastly, 493 the sample size of the ultrasound dataset was small, especially for the m. rectus femoris, since we were 494 unable to process the data of some older patients with DMD due to muscle border invisibility caused 495 by severe muscle degeneration. Therefore, the results of ultrasound dataset should be interpreted 496 with caution.

497

Despite the limitations, this study has established longitudinal trajectories of muscle impairments, consisting of muscle strength, contractures and muscle size alterations, in a cohort of growing boys with DMD covering the ambulation period. These longitudinal trajectories are valuable for enhancing our understanding of the relationship between muscle impairments and progressive gait pathology in DMD. Moreover, the results revealed sensitive outcome measures, which could enhance clinical trial design to detect the efficacy of novel therapeutic strategies.

504 Acknowledgments

- 505 The authors wish to thank all the children and parents for their participation in this study. We also
- thank the colleagues of the University Hospital of Leuven involved in the recruitment. A special thank
- 507 you to Elze Stoop and Ester Huyghe for their support in data collection and processing.

508 References

- Sutherland DH, Olshen R, Cooper L, Wyatt M, Leach J, Mubarak S, et al. The pathomechanics
 of gait in Duchenne Muscular Dystrophy. Dev Med Child Neurol. 1981;23: 3–22.
 doi:10.1111/j.1469-8749.1981.tb08442.x
- Sussman M. Duchenne Muscular Dystrophy. J Am Acad Orthop Surg. 2002;10: 138–51.
 doi:10.5435/00124635-200203000-00009
- Emery AEH. Population Frequencies of Inherited Neuromuscular diseases -a World Survey.
 Neuromuscul Disord. 1991;1: 19–29. doi:10.1016/0960-8966(91)90039-u
- Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the
 sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A.
 1993;90: 3710–4. doi:10.1073/pnas.90.8.3710
- Moens P, Baatsen PHWW, Maréchal G. Increased susceptibility of EDL muscles from mdx mice
 to damage induced by contraction with stretch. J Muscle Res Cell Motil. 1993;14: 446–51.
 doi:10.1007/BF00121296
- 5226.Lindsay A, Baumann CW, Rebbeck RT, Yuen SL, Southern WM, Hodges JS, et al. Mechanical523factors tune the sensitivity of mdx muscle to eccentric strength loss and its protection by524antioxidant and calcium modulators. Skelet Muscle. 2020;10: 3. doi:10.1186/s13395-020-5250221-2
- 5267.Jones D, Round J, de Haan A. Skeletal muscles, from molecules to movement. A textbook of527muscle physiology for sport exercise, physiotherapy and medicine. London, UK: Elsevier; 2010.
- Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012;23: 675–87.
 doi:10.1016/j.pmr.2012.06.009
- Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, et al. Quantitative MRI
 and strength measurements in the assessment of muscle quality in Duchenne muscular
 dystrophy. Neuromuscul Disord. 2014;24: 409–16. doi:10.1016/j.nmd.2014.01.015
- Goemans N, Signorovitch J, McDonald C, Mercuri E, Niks E, Wong B, et al. Functional
 trajectories of upper limb and pulmonary function before and after loss of ambulation in
 Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31: S47–S162.
 doi:10.1016/j.nmd.2021.07.148
- Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet
 Neurology. 2018. pp. 251–267. doi:10.1016/S1474-4422(18)30024-3
- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and
 management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and
 psychosocial management. Lancet Neurol. 2010;9: 77–93. doi:10.1016/S1474-4422(09)70271 6
- Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life
 expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre
 between 1981 and 2011. Ann Phys Rehabil Med. 2013;56: 443–54.
 doi:10.1016/j.rehab.2013.06.002
- 55014.Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmüller H. Life expectancy551at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J

552 Epidemiol. 2020;35: 643–653. doi:10.1007/s10654-020-00613-8

- Rideau Y, Duport G, Delaubrier A, Guillou C, Renardel-Irani A, Bach J. Early treatment to
 preserve quality of locomotion for children with Duchenne muscular dystrophy. Semin
 Neurol. 1995;15: 9–17. doi:10.1055/s-2008-1041001
- Bakker JPJ, de Groot IJM, Beckerman H, de Jong BA, Lankhorst GJ. The effects of knee-anklefoot orthoses in the treatment of Duchenne muscular dystrophy: Review of the literature. Clin
 Rehabil. 2000;14: 343–59. doi:10.1191/0269215500cr319oa
- 559 17. Khodadadeh S, McClelland MR, Patrick JH, Edwards RHT, Evans GA. Knee Moments in
 560 Duchenne Muscular Dystrophy. Lancet. 1986;2: 544–5. doi:10.1016/s0140-6736(86)90114-5
- 18. de Souza MA, Figueiredo MML, de Baptista CRDJA, Aldaves RD, Mattiello-Sverzut AC.
 Beneficial effects of ankle-foot orthosis daytime use on the gait of Duchenne muscular
 dystrophy patients. Clin Biomech. 2016;35: 102–110. doi:10.1016/j.clinbiomech.2016.04.005
- 56419.Eagle M. Report on the Muscular Dystrophy Campaign workshop: Exercise in neuromuscular565diseases Newcastle, January 2002. Neuromuscul Disord. 2002;12: 975–83. doi:10.1016/s0960-5668966(02)00136-0
- 567 20. Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for
 568 Duchenne muscular dystrophy. Lancet Neurol. 2022;21: 814–829. doi:10.1016/S1474569 4422(22)00125-9
- 570 21. Ricci G, Bello L, Torri F, Schirinzi E, Pegoraro E, Siciliano G. Therapeutic opportunities and
 571 clinical outcome measures in Duchenne muscular dystrophy. Neurol Sci. 2022;43: 625–633.
 572 doi:10.1007/s10072-022-06085-w
- 573 22. Goemans N, Van den Hauwe M, Signorovitch J, Swallow E, Song J, Colloborative Trajectory
 574 Analysis Project (cTAP). Individualized prediction of changes in 6-minute walk distance for
 575 patients with Duchenne muscular dystrophy. PLoS One. 2016;11: e0164684.
 576 doi:10.1371/journal.pone.0164684
- 577 23. Goemans N. Therapy development and clinical outcome measures for Duchenne muscular
 578 dystrophy [PhD thesis]. Leuven: KU Leuven; 2013.
- 579 24. McDonald CM, Abresch RT, Carter GT, Fowler WM, Johnson ER, Kilmer DD, et al. Profiles of
 580 Neuromuscular Diseases. Duchenne Muscular Dystrophy. Am J Phys Med Rehabil. 1995;74:
 581 S70-92. doi:10.1097/00002060-199509001-00003
- Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, et al. Clinical evaluator
 reliability for quantitative and manual muscle testing measures of strength in children. Muscle
 and Nerve. 2001;24: 787–93. doi:10.1002/mus.1070
- 585 26. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, et al. Reliable
 586 surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
 587 Muscle and Nerve. 2007;35: 36–42. doi:10.1002/mus.20654
- 58827.Bohannon RW. Manual muscle testing: does it meet the standards of an adequate screening589test? Clin Rehabil. 2005;19: 662–7. doi:10.1191/0269215505cr873oa
- Mathur S, Lott DJ, Senesac C, Germain SA, Vohra RS, Sweeney HL, et al. Age-Related
 Differences in Lower-Limb Muscle Cross-Sectional Area and Torque Production in Boys With
 Duchenne Muscular Dystrophy. Arch Phys Med Rehabil. 2010;91: 1051–8.
 doi:10.1016/j.apmr.2010.03.024
- 594 29. Buckon C, Sienko S, Bagley A, Sison M, Fowler E, Staudt L, et al. Can Quantitative Muscle
 595 Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids
 596 in Ambulatory Boys with Duchenne Muscular Dystrophy? PLoS Curr. 2016;8:

597 598		ecurrents.md.1ced64dff945f8958221fddcd4ee60b0. doi:10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
599 600 601	30.	Beenakker EAC, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol. 2005;9: 387–93. doi:10.1016/j.ejpn.2005.06.004
602 603 604 605	31.	Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, Napolitano S, et al. Quantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures. BMC Neurol. 2012;12: 91. doi:doi: 10.1186/1471-2377-12-91
606 607 608	32.	Leon M, Roza D, Davoli G, Baptista C, Sobreira C, Mattiello-Sverzut A. Generation of percentile curves for strength and functional abilities for boys with Duchenne muscular dystrophy. Muscle and Nerve. 2023;68: 198–205. doi:10.1002/mus.27921
609 610 611 612	33.	Buckon CE, Sienko SE, Fowler EG, Bagley AM, Staudt LA, Sison-Williamson M, et al. A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2022;9: 321–334. doi:10.3233/JND-210704
613 614 615	34.	Willcocks RJ, Barnard AM, Wortman RJ, Senesac CR, Lott DJ, Harrington AT, et al. Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function. J Neuromuscul Dis. 2022;9: 289–302. doi:10.3233/JND-210731
616 617 618	35.	Choi Y-A, Chun S-M, Kim Y, Shin H-I. Lower extremity joint contracture according to ambulatory status in children with Duchenne muscular dystrophy. BMC Musculoskelet Disord. 2018;19: 287. doi:10.1186/s12891-018-2212-6
619 620 621 622	36.	McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391: 451–461. doi:10.1016/S0140-6736(17)32160-8
623 624 625 626	37.	Kiefer M, Bonarrigo K, Quatman-Yates C, Fowler A, Horn PS, Wong BL. Progression of Ankle Plantarflexion Contractures and Functional Decline in Duchenne Muscular Dystrophy: Implications for Physical Therapy Management. Pediatr Phys Ther. 2019;31: 61–66. doi:10.1097/PEP.000000000000553
627 628 629	38.	Mudge AJ, Bau K V., Purcell LN, Wu JC, Axt MW, Selber P, et al. Normative reference values for lower limb joint range, bone torsion, and alignment in children aged 4-16 years. J Pediatr Orthop Part B. 2014;23: 15–25. doi:10.1097/BPB.0b013e328364220a
630 631	39.	Sankar WN, Laird CT, Baldwin KD. Hip range of motion in children: What is the norm? J Pediatr Orthop. 2012;32: 399–405. doi:10.1097/BPO.0b013e3182519683
632 633 634	40.	Lee SY, Lee SH, Chung CY, Park MS, Lee KM, Akhmedov B, et al. Age-related changes in physical examination and gait parameters in normally developing children and adolescents. J Pediatr Orthop Part B. 2013;22: 153–7. doi:10.1097/BPB.0b013e32835b2e7f
635 636 637 638	41.	Sherlock SP, Palmer J, Wagner KR, Abdel-Hamid HZ, Bertini E, Tian C, et al. Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. J Neurol. 2022;269: 4421–4435. doi:10.1007/s00415-022-11084-0
639 640 641	42.	Sherlock SP, Zhang Y, Binks M, Marraffino S. Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests. Biomark Med. 2021;15: 761–773. doi:10.2217/bmm-2020-0801

- Godi C, Ambrosi A, Nicastro F, Previtali SC, Santarosa C, Napolitano S, et al. Longitudinal MRI
 quantification of muscle degeneration in Duchenne muscular dystrophy. Ann Clin Transl
 Neurol. 2016;3: 607–22. doi:10.1002/acn3.319
- A4. Nagy S, Schädelin S, Hafner P, Bonati U, Scherrer D, Ebi S, et al. Longitudinal reliability of
 outcome measures in patients with Duchenne muscular dystrophy. Muscle and Nerve.
 2020;61: 63–68. doi:10.1002/mus.26690
- 648 45. Ropars J, Gravot F, Ben Salem D, Rousseau F, Brochard S, Pons C. Muscle MRI: A biomarker of
 649 disease severity in Duchenne muscular dystrophy? A systematic review. Neurology. 2020;94:
 650 117–133. doi:10.1212/WNL.00000000008811
- 46. Vill K, Sehri M, Müller C, Hannibal I, Huf V, Idriess M, et al. Qualitative and quantitative muscle
 ultrasound in patients with Duchenne muscular dystrophy: Where do sonographic changes
 begin? Eur J Paediatr Neurol. 2020;28: 142–150. doi:10.1016/j.ejpn.2020.06.001
- 47. Jansen M, van Alfen N, Nijhuis van der Sanden MWG, van Dijk JP, Pillen S, de Groot IJM.
 Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne
 muscular dystrophy. Neuromuscul Disord. 2012;22: 306–17. doi:10.1016/j.nmd.2011.10.020
- 48. Zaidman CM, Malkus EC, Connolly AM. Muscle Ultrasound Quantifies Disease Progression
 Over Time in Infants and Young Boys with Duchenne Muscular Dystrophy. Muscle Nerve.
 2015;52: 334–8. doi:10.1002/mus.24609
- Bulut N, Karaduman A, Alemdaroğlu-Gürbüz İ, Yilmaz Ö, Topaloğlu H, Özçakar L.
 Ultrasonographic assessment of lower limb muscle architecture in children with early-stage
 Duchenne muscular dystrophy. Arq Neuropsiquiatr. 2022;80: 475–481. doi:10.1590/0004282X-ANP-2021-0038
- 664 50. Pillen S, Verrips A, van Alfen N, Arts IMP, Sie LTL, Zwarts MJ. Quantitative skeletal muscle
 665 ultrasound: Diagnostic value in childhood neuromuscular disease. Neuromuscul Disord.
 666 2007;17: 509–16. doi:10.1016/j.nmd.2007.03.008
- 667 51. Morse CI, Smith J, Denny A, Tweedale J, Searle ND. Gastrocnemius medialis muscle
 668 architecture and physiological cross sectional area in adult males with Duchenne muscular
 669 dystrophy. J Musculoskelet Neuronal Interact. 2015;15: 154–60.
- 52. Vandekerckhove I, Hanssen B, Peeters N, Dewit T, De Beukelaer N, Van den Hauwe M, et al.
 Anthropometric-related percentile curves for muscle size and strength of lower limb muscles
 of typically developing children. medRxiv Prepr. 2024. doi:10.1101/2024.03.27.24304866
- 673 53. Goudriaan M, Nieuwenhuys A, Schless S, Goemans N, Molenaers G, Desloovere K. A new
 674 strength assessment to evaluate the association between muscle weakness and gait
 675 pathology in children with cerebral palsy. PLoS One. 2018;13: e0191097.
 676 doi:10.1371/journal.pone.0191097
- 54. Verreydt I, Vandekerckhove I, Stoop E, Peeters N, van Tittelboom V, Van de Walle P, et al.
 Instrumented strength assessment in typically developing children and children with a neural
 or neuromuscular disorder: A reliability, validity and responsiveness study. Front Physiol.
 2022;13: 855222. doi:10.3389/fphys.2022.855222
- 681 55. Cenni F, Monari D, Desloovere K, Aertbeliën E, Schless SH, Bruyninckx H. The reliability and
 682 validity of a clinical 3D freehand ultrasound system. Comput Methods Programs Biomed.
 683 2016;136: 179–87. doi:10.1016/j.cmpb.2016.09.001
- 56. Hanssen B, Peeters N, Dewit T, Huyghe E, Dan B, Molenaers G, et al. Reliability of 3D freehand
 ultrasound to assess lower limb muscles in children with spastic cerebral palsy and typical
 development. J Anat. 2023;242: 986–1002. doi:10.1111/joa.13839

- 57. Cenni F, Schless SH, Monari D, Bar-On L, Aertbeliën E, Bruyninckx H, et al. An innovative
 solution to reduce muscle deformation during ultrasonography data collection. J Biomech.
 2018;77: 194–200. doi:10.1016/j.jbiomech.2018.06.002
- 58. Peeters N, Hanssen B, De Beukelaer N, Vandekerckhove I, Walhain F, Huyghe E, et al. A
 comprehensive normative reference database of muscle morphology in typically developing
 children aged 3–18 years—a cross-sectional ultrasound study. J Anat. 2023;242: 754–770.
 doi:10.1111/joa.13817
- 59. Vandekerckhove I, Van den Hauwe M, De Beukelaer N, Stoop E, Goudriaan M, Delporte M, et
 al. Longitudinal Alterations in Gait Features in Growing Children With Duchenne Muscular
 Dystrophy. Front Hum Neurosci. 2022;16: 861136. doi:10.3389/fnhum.2022.861136
- 697 60. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New-York: Springer
 698 Series in Statistics, Springer-Verlag; 2000.
- 699 61. Verbeke G, Molenberghs G. Linear mixed models in practice: a SAS-oriented approach. New700 York: Springer; 1997.
- Connolly A, Florence J, Cradock M, Eagle M, Flanigan K, McDonald C, et al. One year outcome
 of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler
 development. Pediatr Neurol. 2014;50: 557–63. doi:10.1016/j.pediatrneurol.2014.02.006
- 63. Henricson E, Abresch R, Han JJ, Nicorici A, Keller EG, Elfring G, et al. Percent-predicted 6minute walk distance in duchenne muscular dystrophy to account for maturational influences.
 PLoS Curr. 2012;4: RRN1297. doi:10.1371/currents.RRN1297

707 Supporting information

- 708 S1 Fig. Predicted longitudinal trajectories for muscle strength deficits of hip muscles (a), knee
- 709 muscles (b) and ankle muscles (c) with age for boys with DMD of linear mixed effect models. The
- 710 average predicted trajectory (black thick line), the individual predicted profiles (colored thinner lines),
- and the actual observed outcomes (colored dots) are displayed. Each color represents one patient with
- 712 DMD. The estimates for the fixed effects are given in Supplementary Table 1. DMD, Duchenne
- 713 muscular dystrophy
- 714

715 S1 Table. Fixed effects of linear mixed effect models for the longitudinal trajectories of the muscle

716 strength deficits with age for boys with DMD

- p-values in bold indicate significance level at p < 0.05.
- The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
- 719 age²; β_3 = regression slope of age³.

720 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj,

721 subjects

722

723	S2 Fig. Predicted longitudinal trajectories for absolute (left column) and non-dimensional (right
724	column) knee extension ROM (a), Hamstrings ROM (b), ankle dorsiflexion with knee extended (c)
725	and ankle dorsiflexion with knee flexed (d) with age for boys with DMD of linear mixed effect
726	models. The average predicted trajectory (black thick line), the individual predicted profiles (colored
727	thinner lines), and the actual observed outcomes (colored dots) are displayed. Each color represents
728	one patient with DMD. The estimates for the fixed effects are given in Supplementary Table 2. DMD,
729	Duchenne muscular dystrophy; ROM, range of motion.
730	
731	S2 Table. Fixed effects of linear mixed effect models for the longitudinal trajectories of the absolute
732	and non-dimensional ROMs with age for boys with DMD
733	p-values in bold indicate significance level at p < 0.05.
734	The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
735	age ² ; β_3 = regression slope of age ³ .
736	CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; ROM,
737	range of motion; subj, subjects
738	
739	S3 Fig. Predicted longitudinal trajectories for muscle size deficits with age for boys with DMD of
740	linear mixed effect models. The average predicted trajectory (black thick line), the individual predicted
741	profiles (colored thinner lines), and the actual observed outcomes (colored dots) are displayed. Each
742	color represents one patient with DMD. The estimates for the fixed effects are given in Supplementary
743	Table 3. DMD, Duchenne muscular dystrophy

745 S3 Table. Fixed effects of linear mixed-effect models for the longitudinal trajectories of the muscle

746 size alterations with age for boys with DMD

- p-values in bold indicate significance level at p < 0.05.
- The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
- 749 age².
- 750 CI, 95% confidence interval; CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; n,
- 751 number; o, observations; subj, subjects
- 752

```
753 S4 Fig. Overview of the participants medical and clinical background. Each color represents one
```

- 754 patient with DMD.
- AFO, ankle foot orthosis; DMD, Duchenne muscular dystrophy; LA, loss of ambulation

756

S5 Fig. Data exploration of longitudinal trajectories for absolute (left column) and non-dimensional (right column) hip extension ROM (a) and hip adduction ROM (b) with age for boys with DMD of linear mixed effect models. The Loess regression (black thick line) and the actual observed outcomes (colored symbols) are displayed. Each color represents one patient with DMD. DMD, Duchenne muscular dystrophy; ROM, range of motion.

762

```
    S4 Table. Estimates of random-effect and residual covariance structure of piecewise models for the
    longitudinal trajectories of the muscle impairments with age for boys with DMD
```

765 The following symbols represent: σ^2 =variance; a_{i0} = random intercept; b_i = random slope; b_{i1} = random

slope for regression slope before breakpoint; b_{i2} = random slope for regression slope after breakpoint;

767 ϵ_{ij} = measurement error.

768 CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; ROM, range of motion;

770 S5 Table. Estimates of random-effect and residual covariance structure of linear mixed-effect models

771 for the longitudinal trajectories of the muscle impairments with age for boys with DMD

- The following symbols represent: σ^2 =variance; a_{i0} = random intercept; b_{i1} = random slope for regression
- slope of age; ε_{ij} = measurement error.
- CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; ROM, range of motion;



Fig1



Fig2

Fig3